Difference between revisions of "Sacituzumab govitecan (Trodelvy)"
Jump to navigation
Jump to search
Warner-admin (talk | contribs) |
Warner-admin (talk | contribs) |
||
| Line 3: | Line 3: | ||
==Diseases for which it is used== | ==Diseases for which it is used== | ||
| + | *[[Bladder cancer]] | ||
*[[Breast_cancer,_triple_negative|TNBC]] | *[[Breast_cancer,_triple_negative|TNBC]] | ||
| Line 22: | Line 23: | ||
[[Category:Topoisomerase inhibitors]] | [[Category:Topoisomerase inhibitors]] | ||
| + | [[Category:Bladder cancer medications]] | ||
[[Category:Breast cancer medications]] | [[Category:Breast cancer medications]] | ||
[[Category:FDA approved in 2020]] | [[Category:FDA approved in 2020]] | ||
Revision as of 01:41, 14 April 2021
Mechanism of action
From the NCI Drug Dictionary: An antibody-drug conjugate containing the humanized monoclonal antibody, hRS7, against tumor-associated calcium signal transducer 2 (TACSTD2 or TROP2) and linked to the active metabolite of irinotecan, 7-ethyl-10-hydroxycamptothecin (SN-38), with potential antineoplastic activity. The antibody moiety of sacituzumab govitecan selectively binds to TROP2. After internalization and proteolytic cleavage, SN-38 selectively stabilizes topoisomerase I-DNA covalent complexes, resulting in DNA breaks that inhibit DNA replication and trigger apoptosis.
Diseases for which it is used
History of changes in FDA indication
- 4/22/2020: Granted accelerated approval for adult patients with metastatic triple-negative breast cancer who received at least two prior therapies for metastatic disease.
- 4/7/2021: Granted regular approval for patients with unresectable locally advanced or metastatic triple-negative breast cancer (mTNBC) who have received two or more prior systemic therapies, at least one of them for metastatic disease.
- 4/13/2021: Granted accelerated approval for patients with locally advanced or metastatic urothelial cancer (mUC) who previously received a platinum-containing chemotherapy and either a programmed death receptor-1 (PD-1) or a programmed death-ligand 1 (PD-L1) inhibitor.
Also known as
- Code names: IMMU-132, RS7-SN38
- Generic name: sacituzumab govitecan-hziy
- Brand name: Trodelvy